Analysis of United States Drug Patent 9,814,708
Patent 9,814,708, granted to Bristol-Myers Squibb Company on November 14, 2017, claims methods of treating cancer by administering nivolumab. The patent covers specific dosage regimens and combinations of nivolumab with other therapeutic agents. This analysis details the patent's scope, key claims, and the surrounding competitive patent landscape.
What is the Core Invention Claimed in Patent 9,814,708?
Patent 9,814,708 primarily claims methods of treating cancer using nivolumab. The patent is structured around specific treatment protocols, including dosage amounts, frequency of administration, and combinations with other drugs.
What are the Key Claims of Patent 9,814,708?
The patent includes multiple independent and dependent claims that define the scope of the invention.
Independent Claims:
- Claim 1: A method of treating cancer, comprising administering to a subject in need thereof an effective amount of nivolumab, wherein nivolumab is administered at a dose of approximately 1 mg/kg to 10 mg/kg of body weight.
- Claim 4: A method of treating cancer, comprising administering to a subject in need thereof an effective amount of nivolumab, wherein nivolumab is administered once every two weeks.
- Claim 7: A method of treating cancer, comprising administering to a subject in need thereof an effective amount of nivolumab in combination with ipilimumab, wherein nivolumab is administered at a dose of approximately 1 mg/kg to 3 mg/kg of body weight.
- Claim 10: A method of treating cancer, comprising administering to a subject in need thereof an effective amount of nivolumab in combination with ipilimumab, wherein nivolumab is administered once every three weeks and ipilimumab is administered once every three weeks.
Dependent Claims:
These claims further refine the independent claims by specifying particular types of cancer, dosage ranges, or administration schedules. For example, dependent claims might specify:
- Treating melanoma, non-small cell lung cancer, or renal cell carcinoma.
- Administering nivolumab at a dose of 3 mg/kg.
- Administering nivolumab every four weeks.
- Administering ipilimumab at a dose of 1 mg/kg.
The claims are not limited to specific formulations of nivolumab, focusing instead on the method of use and the therapeutic outcome. The patent emphasizes the administration of nivolumab as a monotherapy or in combination with ipilimumab for various cancer types.
What is the Scope of the Protected Invention?
The scope of Patent 9,814,708 is defined by its claims, which cover the use of nivolumab in specific treatment regimens for cancer.
What are the Specific Cancer Types Covered?
While the claims broadly refer to "cancer," the patent's background and examples often reference specific oncological indications where nivolumab has demonstrated efficacy. These commonly include:
- Melanoma
- Non-Small Cell Lung Cancer (NSCLC)
- Renal Cell Carcinoma (RCC)
- Hodgkin Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer (specifically microsatellite instability-high)
- Urothelial Carcinoma
The patent’s coverage extends to the method of treating these cancers using the defined administration protocols.
What are the Dosage and Administration Parameters Defined?
The patent specifies several key parameters for the administration of nivolumab and its combination therapy:
- Nivolumab Dosage (Monotherapy): Approximately 1 mg/kg to 10 mg/kg of body weight. A specific preferred dose mentioned is 3 mg/kg.
- Nivolumab Administration Frequency (Monotherapy): Commonly once every two weeks or once every four weeks.
- Nivolumab Dosage (Combination with Ipilimumab): Approximately 1 mg/kg to 3 mg/kg of body weight.
- Nivolumab Administration Frequency (Combination with Ipilimumab): Once every three weeks.
- Ipilimumab Administration Frequency (Combination with Nivolumab): Once every three weeks.
These parameters are central to defining what constitutes infringement of the patent.
How Does Patent 9,814,708 Relate to Nivolumab's Regulatory Approval?
Nivolumab is marketed as Opdivo by Bristol-Myers Squibb. Patent 9,814,708 is a method of use patent that supports the commercialization of Opdivo by protecting specific treatment strategies.
What is the Mechanism of Action of Nivolumab?
Nivolumab is a human immunoglobulin G4 (IgG4) kappa isotype monoclonal antibody that binds to the programmed death-1 (PD-1) receptor. PD-1 is an immune checkpoint receptor expressed on T cells. Binding of PD-1 to its ligands, PD-L1 and PD-L2, inhibits T-cell activation and proliferation, thereby suppressing the immune response. By blocking the interaction between PD-1 and its ligands, nivolumab reinvigorates anti-tumor immune responses.
How Do the Patent Claims Align with Approved Indications and Dosing?
The claims of Patent 9,814,708 align with and protect the approved indications and dosing regimens of Opdivo. For instance, Opdivo is approved for various cancers, including:
- Advanced Melanoma: Often treated with nivolumab monotherapy at 3 mg/kg every two weeks, or in combination with ipilimumab.
- Advanced NSCLC: Approved for first-line treatment in combination with ipilimumab and platinum-doublet chemotherapy, or as monotherapy in subsequent lines of treatment. Specific dosing for monotherapy is typically 3 mg/kg every two weeks.
- Advanced RCC: Approved for first-line treatment in combination with ipilimumab.
The patent provides a layer of intellectual property protection for these specific therapeutic applications.
What is the Patent Landscape for Nivolumab and Related Therapies?
The patent landscape for immunotherapies, particularly PD-1 inhibitors like nivolumab, is complex and highly competitive, involving numerous patents covering different aspects of the technology.
Who are the Key Patent Holders in the PD-1/PD-L1 Inhibitor Space?
Beyond Bristol-Myers Squibb, other major players hold significant patent portfolios in this area:
- Merck & Co. (Keytruda): Holds patents related to pembrolizumab, its PD-1 inhibitor.
- Roche (Tecentriq): Holds patents related to atezolizumab, its PD-L1 inhibitor.
- AstraZeneca (Imfinzi, Imjudo): Holds patents related to durvalumab (PD-L1) and tremelimumab (CTLA-4).
- Regeneron Pharmaceuticals: Holds patents related to cemiplimab (PD-1).
These companies have broad patent coverage extending from the antibodies themselves to their therapeutic uses, manufacturing processes, and diagnostic methods.
What Types of Patents Exist in this Landscape?
The patent landscape includes several categories of patents relevant to nivolumab:
- Composition of Matter Patents: Protecting the nivolumab molecule itself. These are often the earliest and broadest patents.
- Method of Use Patents: Protecting specific methods of treating diseases, such as Patent 9,814,708, which covers particular dosage regimens and combinations.
- Formulation Patents: Protecting specific pharmaceutical compositions and delivery methods.
- Manufacturing Process Patents: Protecting methods for producing the antibody.
- Diagnostic Patents: Protecting methods for identifying patients likely to respond to treatment (e.g., PD-L1 expression testing).
How Does Patent 9,814,708 Fit within this Broader Landscape?
Patent 9,814,708 is a method of use patent that complements the broader intellectual property strategy for nivolumab. While the composition of matter patents may have expired or be nearing expiration, method of use patents can extend market exclusivity by protecting specific, commercially valuable ways of using the drug. These patents are crucial for defending market share against generic competition, particularly for approved indications.
What are the Implications of Patent 9,814,708 for Competitors and Investors?
This patent influences strategic decisions for pharmaceutical companies developing competing immunotherapies and for investors evaluating the market.
How Might Competitors Navigate This Patent?
Competitors developing similar PD-1 inhibitors must carefully design their treatment regimens to avoid direct infringement of the specific claims in Patent 9,814,708. This might involve:
- Alternative Dosages: Utilizing dosages outside the 1 mg/kg to 10 mg/kg range for monotherapy or the 1 mg/kg to 3 mg/kg range for combination therapy.
- Different Administration Frequencies: Employing administration schedules other than "once every two weeks" or "once every three weeks" as specified in the claims.
- Combination with Different Agents: Using nivolumab in combination with therapeutic agents other than ipilimumab, or developing combination therapies that do not fall within the claimed parameters.
- Targeting Different Indications: Focusing on cancer types not explicitly or implicitly covered by the patent's intended scope, although broad method of use patents can be challenging to circumvent.
- Challenging Patent Validity: Investigating grounds to invalidate the patent, such as lack of novelty or obviousness, although this is a high-risk strategy.
What are the Investment Considerations?
For investors, Patent 9,814,708 impacts the projected market exclusivity and profitability of nivolumab-based therapies.
- Market Exclusivity: The patent helps to safeguard Bristol-Myers Squibb's revenue streams from Opdivo by preventing competitors from utilizing these specific, proven treatment protocols.
- Patent Expiration: Investors must consider the remaining term of this patent. Upon expiration, generic or biosimilar manufacturers may be able to adopt the patented treatment methods, potentially increasing competition and reducing prices.
- Pipeline Value: The strength and breadth of a company's patent portfolio, including method of use patents, are critical factors in assessing the long-term value of its drug pipeline and its ability to defend market position.
- Litigation Risk: Investors should be aware of potential patent litigation that could arise if competitors are perceived to be infringing these claims.
How is Patent 9,814,708 Enforced?
Enforcement typically involves legal action taken by the patent holder against entities that are alleged to be infringing the patent's claims.
What Constitutes Infringement?
Infringement occurs when a party makes, uses, sells, offers to sell, or imports a patented invention within the United States without the permission of the patent holder. For Patent 9,814,708, infringement would likely involve administering nivolumab to a patient according to the precise method claims outlined in the patent, such as a specific dosage or frequency for a particular cancer type.
What are the Typical Enforcement Actions?
- Cease and Desist Letters: The patent holder may first send a letter to the alleged infringer outlining the patent and demanding that they stop the infringing activity.
- Litigation: If the infringing activity continues, the patent holder can file a lawsuit in federal court seeking remedies such as:
- Injunctions: A court order prohibiting the infringer from continuing their activities.
- Damages: Monetary compensation for the harm caused by the infringement, which can include lost profits or a reasonable royalty.
- Post-Grant Review (PGR) and Inter Partes Review (IPR): Competitors or other parties may challenge the validity of the patent through administrative proceedings at the U.S. Patent and Trademark Office (USPTO).
The enforcement of method of use patents like 9,814,708 is critical for patent holders to maintain their competitive advantage and recoup R&D investments.
Conclusion
Patent 9,814,708 is a crucial method of use patent for Bristol-Myers Squibb, providing specific protection for the administration of nivolumab in treating various cancers. Its claims, detailing particular dosage regimens and combinations, are designed to extend market exclusivity and defend against competitive therapies. The patent operates within a dynamic and crowded landscape of intellectual property surrounding PD-1/PD-L1 inhibitors, requiring careful navigation by competitors and strategic consideration by investors.
Key Takeaways
- Patent 9,814,708 protects methods of treating cancer using nivolumab, focusing on specific dosage ranges (1-10 mg/kg monotherapy, 1-3 mg/kg combination) and administration frequencies (e.g., every two or three weeks).
- The patent's claims align with approved therapeutic uses and dosing for Opdivo, including indications like melanoma and NSCLC.
- This method of use patent complements broader composition of matter and formulation patents, contributing to market exclusivity for nivolumab.
- Competitors must design their therapies to avoid infringement by altering dosages, frequencies, or combination agents.
- The patent's remaining term is a key consideration for investors regarding future market competition and profitability.
FAQs
- Does Patent 9,814,708 cover the nivolumab molecule itself?
No, Patent 9,814,708 is a method of use patent. It claims the specific method of administering nivolumab, not the composition of the antibody molecule.
- What is the primary cancer type that this patent is intended to protect the treatment of?
While the patent claims broadly cover "cancer," its examples and alignment with regulatory approvals indicate primary protection for indications such as melanoma, non-small cell lung cancer, and renal cell carcinoma.
- Can a generic version of nivolumab be sold if this patent is still active?
A generic version of nivolumab could potentially be sold, but it would be restricted from using the specific methods of treatment claimed in Patent 9,814,708. Manufacturers would need to offer alternative dosing or combination regimens.
- How does Patent 9,814,708 differ from patents covering ipilimumab?
Patent 9,814,708 specifically claims methods involving nivolumab, either alone or in combination with ipilimumab. Patents covering ipilimumab would claim methods related to the administration of ipilimumab itself.
- What is the significance of the "approximately" in the dosage claims?
The term "approximately" provides some flexibility within the claimed dosage ranges. However, significant deviations from the stated ranges would likely fall outside the scope of the patent.
Citations
[1] Bristol-Myers Squibb Company. (2017). Method of treating cancer. U.S. Patent 9,814,708 B2. Retrieved from USPTO Patent Full-Text and Image Database
